Drug Profile
XL 413
Alternative Names: BMS-863233; EXEL 5413; XL-413Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Exelixis
- Developer Bristol-Myers Squibb; Exelixis
- Class Antineoplastics; Small molecules
- Mechanism of Action CDC7 protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haematological malignancies; Solid tumours
Most Recent Events
- 11 Aug 2010 Bristol-Myers Squibb and Exelixis terminate phase I/II trial [NCT00838890] in refractory Haematological malignancies in USA
- 11 Aug 2010 Bristol-Myers Squibb and Exelixis terminate phase I/II trial [NCT00886782] in late-stage and/or metastatic Solid tumours in USA, Canada and France
- 27 Nov 2008 Exelixis and Bristol-Myers Squibb select to co-develop XL 413 in the US